Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Genocea Biosciences's EBITDA for the
three
months ended in Mar. 2022 was $-15.35 Mil. Genocea Biosciences's Revenue for the
three
months ended in Mar. 2022 was $0.27 Mil. Therefore, Genocea Biosciences's EBITDA margin for the quarter that ended in Mar. 2022 was -5,684.07%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Genocea Biosciences EBITDA Margin % Related Terms
Genocea Biosciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Genocea Biosciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0A51 vs FNAM, BXRX, XSNX: EBITDA Margin % Comparison
For the Biotechnology subindustry, Genocea Biosciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genocea Biosciences EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genocea Biosciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Genocea Biosciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genocea Biosciences (LTS:0A51) has a EBITDA Margin % of -5,684.07% as of Mar. 2022. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Genocea Biosciences and its competitors.
Is Genocea Biosciences' EBITDA Margin % too high?
Genocea Biosciences' current EBITDA Margin % is -5,684.07%. Overall, Genocea Biosciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Genocea Biosciences' EBITDA Margin % compare to FNAM and BXRX?
Genocea Biosciences' EBITDA Margin % of -5,684.07% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Genocea Biosciences and its competitors. Genocea Biosciences's current EBITDA Margin % is -5,684.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genocea Biosciences stock overvalued right now?
Genocea Biosciences (LTS:0A51) has a current EBITDA Margin % of -5,684.07%. The current EBITDA Margin % is -5,684.07%. Genocea Biosciences' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Genocea Biosciences (LTS:0A51), the current EBITDA Margin % is -5,684.07% as of Mar. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Genocea Biosciences Inc is a USA-based biopharmaceutical company discovering and developing novel cancer immunotherapies using its proprietary ATLAS platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, or Inhibigens , that drive pro-tumor immune responses.
16GF Score
Get the complete analysis for LTS:0A51
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0A51 has been successfully added to your 
